"First, do no harm": Chemotherapy or healthy heart?

Hellenic Journal of Cardiology

Volumn 53, Issue 2, 2012, Pages 127-136

  Dimos, Apostolos K ^a   Stougiannos, Pavlos N ^a   Trikas, Athanasios G ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Cardiotoxicity; Chemotherapy; Heart

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; BLEOMYCIN; BUSULFAN; CAPECITABINE; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; IDARUBICIN; IFOSFAMIDE; IMATINIB; INTERFERON; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN; PACLITAXEL; PENTOSTATIN; RETINOIC ACID; RITUXIMAB; SUNITINIB; TENIPOSIDE; TRASTUZUMAB; UNINDEXED DRUG; VINCA ALKALOID;

ARTICLE; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; EDEMA; ELECTROCARDIOGRAM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; MYOCARDITIS; PERICARDITIS; SINUS BRADYCARDIA; STROKE; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; DRUG TOXICITY; HEART; HEART DISEASES; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84860179620     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007; 7: 61-66.
2. Portera CC, Swain SM. The heart of the matter. J Clin Oncol. 2007; 25: 3794-3796.
3. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355: 1572-1582.
4. Menna P, Salvatorelli E, Minotti G. Cardiotoxicity of antitumor drugs. Chem Res Toxicol. 2008; 21: 978-989.
5. Möller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001; 19: 3173-3181.
6. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007; 25: 3635-3643.
7. Barry E, Alvarez JA, Scully RE, Miller TL, Lipshultz SE. Anthracycline- induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacother. 2007; 8: 1039-1058.
8. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003; 14: 277-281.
9. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol. 2001; 19: 37-43.
10. Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007; 25: 3808-3815.
11. Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab- related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007; 25: 3525-3533.
12. Thomas X, Le QH, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol. 2002; 81: 504-507.
13. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56: 185-229.
14. Salvatorelli E, Menna P, Gianni L, Minotti G. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies. J Pharmacol Exp Ther. 2007; 320: 790-800.
15. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302-2313.
16. McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med. 1989; 111: 273-279.
17. Perotti A, Cresta S, Grasselli G, Capri G, Minotti G, Gianni L. Cardiotoxic effects of anthracycline-taxane combinations. Expert Opin Drug Saf. 2003; 2: 59-71.
18. Schimmel KJ, Richel DJ, van den Brink RB, Guchelaar HJ. Cardiotoxicity of cytotoxic drugs. Cancer Treat Rev. 2004; 30: 181-191.
19. Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of cancer therapy. J Clin Oncol. 2005; 23: 7685-7696.
20. Ozben B, Kurt R, Oflaz H, et al. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient. Clin Appl Thromb Hemost. 2007; 13: 439-442.
21. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118: 31-36.
22. Kontozis L, Soteriou M, Papamichael D, et al. Isolated right atrial metastasis of malignant melanoma mimicking a myxoma. Hellenic J Cardiol. 2011; 52: 281-284.
23. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med. 2007; 357: 39-51.
24. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol. 2005; 23: 2900-2902.
25. Guarneri V, Lenihan DJ, Valero V, et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol. 2006; 24: 4107-4115.
26. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
27. Beauclair S, Formento P, Fischel JL, et al. Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity. Ann Oncol. 2007; 18: 1335-1341.
28. Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxic effects in man: superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep. 1978; 62: 857-864.
29. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989; 118: 92-98.
30. Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994; 33: 645-649.
31. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997; 96: 2641-2648.
32. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109: 2749-2754.
33. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of Bnatriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141: 367-374.
34. Nousiainen T, Jantunen E, Vanninen E, Remes J, Vuolteenaho O, Hartikainen J. Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Eur J Haematol. 1999; 62: 135-141.
35. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin- containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001; 19: 2746-2753.
36. Snowden JA, Hill GR, Hunt P, et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant. 2000; 26: 309-313.
37. Ewer MS, Ali MK, Mackay B, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J Clin Oncol. 1984; 2: 112-117.
38. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol. 1995; 13: 996-1003.
39. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997; 54 Suppl 4: 22-29.
40. Von Hoff DD. Phase I trials of dexrazoxane and other potential applications for the agent. Semin Oncol. 1998; 25: 31-36.
41. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/ AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine. Circulation. 2008; 118: 2596-2648.
42. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2008; 29: 2909-2945.
43. Berliner S, Rahima M, Sidi Y, et al. Acute coronary events following cisplatin-based chemotherapy. Cancer Invest. 1990; 8: 583-586.
44. Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol. 2000; 18: 1725-1732.
45. Schecter JP, Jones SE, Jackson RA. Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP-16-213 (NSC-141540), mediastinal irradiation, or both. Cancer Chemother Rep. 1975; 59: 887-888.
46. Airey CL, Dodwell DJ, Joffe JK, Jones WG. Etoposide-related myocardial infarction. Clin Oncol (R Coll Radiol). 1995; 7: 135.
47. Gradishar WJ, Vokes EE. 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol. 1990; 1: 409-414.
48. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002; 13: 797-801.
49. Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep. 1982; 66: 587-589.
50. Ackrill P, Ralston AJ, Day JP, Hodge KC. Successful removal of aluminium from patient with dialysis encephalopathy. Lancet. 1980; 2: 692-693.
51. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol. 2005; 23: 2574-2576.
52. Cohen MH, Broder LE, Fossieck BE, Ihde DC, Minna JD. Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977; 61: 489-490.
53. Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol. 2000; 27: 347-361.
54. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today (Barc). 2003; 39 Suppl C: 1-16.
55. Saltz LB, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201-1208.
56. Cersosimo RJ. Monoclonal antibodies in the treatment of cancer, Part 2. Am J Health Syst Pharm. 2003; 60: 1631-1641.
57. Soignet SL. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist. 2001; 6 Suppl 2: 11-16.
58. Huang SY, Chang CS, Tang JL, et al. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br J Haematol. 1998; 103: 1092-1095.
59. Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001; 98: 266-271.
60. Rajkumar SV, Gertz MA, Lacy MQ, et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia. 2003; 17: 775-779.
61. Rowinsky EK, McGuire WP, Guarnieri T, Fisherman JS, Christian MC, Donehower RC. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9: 1704-1712.
62. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-652.
63. Fanelli M, Sarmiento R, Gattuso D, et al. Thalidomide: a new anticancer drug? Expert Opin Investig Drugs. 2003; 12: 1211-1225.
64. Jekunen A, Heikkilä P, Maiche A, Pyrhönen S. Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet. 1994; 343: 727-728.
65. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102: 14-25.